INVESTABOT
Equity Research
XNYS · PHARMACEUTICAL PREPARATIONS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-08-13. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-08-06. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-08-05. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
TL;DR: Johnson & Johnson announced that Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, will retire after more than 21 years with the company, with Tom Cavanaugh stepping into th…
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-07-20. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
TL;DR: Johnson & Johnson reported Q2 2026 sales of $25.3 billion, up 6.6% from the prior year, and raised its full-year revenue guidance to $101.1 billion — which would mark the first time in the company's 140-year histo…
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-06-11. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8/13/2026 | Duato Joaquin | CEO and Chairman of the Board | OPTION_EXERCISE | -123,291 | — | — |
| 8/13/2026 | Duato Joaquin | CEO and Chairman of the Board | SELL | -102,315 | $261 | $26,704,215 |
| 8/13/2026 | Duato Joaquin | CEO and Chairman of the Board | SELL | -20,976 | $262 | $5,495,712 |
| 8/13/2026 | Duato Joaquin | CEO and Chairman of the Board | OPTION_EXERCISE | 123,291 | $116 | $14,261,070 |
| 8/6/2026 | Forminard Elizabeth | EVP, Chief Legal Officer | OPTION_EXERCISE | 9,344 | $132 | $1,232,847 |
| 8/6/2026 | Forminard Elizabeth | EVP, Chief Legal Officer | SELL | -9,344 | $258 | $2,408,463 |
| 8/6/2026 | Forminard Elizabeth | EVP, Chief Legal Officer | SELL | -6,574 | $256 | $1,682,497 |
| 8/6/2026 | Forminard Elizabeth | EVP, Chief Legal Officer | OPTION_EXERCISE | -9,344 | — | — |
| 8/5/2026 | Duato Joaquin | CEO and Chairman of the Board | SELL | -41,957 | $258 | $10,827,256 |
| 8/5/2026 | Duato Joaquin | CEO and Chairman of the Board | SELL | -6,523 | $259 | $1,687,755 |
| 7/20/2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | OPTION_EXERCISE | 11,129 | $130 | $1,441,317 |
| 7/20/2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | OPTION_EXERCISE | 11,925 | $132 | $1,573,385 |
| 7/20/2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | SELL | -23,054 | $251 | $5,792,686 |
| 7/20/2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | OPTION_EXERCISE | -11,129 | — | — |
| 7/20/2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | OPTION_EXERCISE | -11,925 | — | — |
| 6/11/2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | OPTION_EXERCISE | 10,000 | $116 | $1,156,700 |
| 6/11/2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | SELL | -10,000 | $241 | $2,411,500 |
| 6/11/2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | OPTION_EXERCISE | -10,000 | — | — |
| 6/9/2026 | Woods Eugene A. | — | GRANT | 161.09 | $233 | $37,500 |
| 6/9/2026 | Pinto Daniel E | — | GRANT | 134.24 | $233 | $31,250 |